Lilly takes its turn in the IL-17 psoriasis data game
This article was originally published in Scrip
Executive Summary
Eli Lilly has followed AstraZeneca and Novartis in releasing promising data for a novel drug acting on interleukin-17 in plaque psoriasis, saying its candidate, ixekizumab, has succeeded in the Phase III UNCOVER studies.